Hemab Therapeutics Holdings, Inc.
Key Metrics
- Previous Close
- $49.16
- 52-Week Range
- $23.00 – $55.42
- Market Cap
- $2.18B
- P/E (TTM)
- —
- EPS (TTM)
- -1.69
- Dividend Yield
- —
Advanced Metrics
- Price/Book
- 4.80
- PEG Ratio
- —
- Return on Equity
- —
- Return on Assets
- —
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Profit Margin
- 0.00%
- Current Ratio
- 35.85
- Debt/Equity
- 0.00
- Total Debt
- $1.03M
- Free Cash Flow
- —
- Revenue Growth
- —
- Earnings Growth
- —
- Enterprise Value
- $1.72B
Market Snapshot
About
Hemab Therapeutics Holdings, Inc. (COAG) is a clinical-stage biotechnology company based in Cambridge, Massachusetts. It is focused on developing novel therapeutic treatments for serious, inherited blood coagulation disorders.
The company's lead candidate is HMB-001, a bispecific antibody. It is being investigated in Phase 1/2 clinical trials for the prophylactic treatment of Glanzmann thrombasthenia and in Phase 2 development for Factor VII deficiency. Hemab's second clinical-stage asset is HMB-002, a monovalent antibody in Phase 1/2 development for the subcutaneous prophylactic treatment of Von Willebrand disease. These programs aim to provide preventative treatments for conditions where current management options are limited.
Hemab's research extends beyond these clinical candidates. The company is also advancing a pipeline of multiple preclinical and discovery-stage assets aimed at other coagulation disorders. Founded in 2020, the company operates with a presence in both the United States and Denmark, leveraging research and development efforts to create new therapies intended to improve outcomes for patients with these challenging conditions.